Advertisement
Screener

PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

PROTHENA CORPORATION PUBLIC LIMITED COMPANY Capital Expenditures

PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Capital Expenditures of $110.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-15.

Discontinued › Cash Flow

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2013-05-15

  • PROTHENA CORPORATION PUBLIC LIMITED COMPANY payments to acquire property, plant, and equipment for the quarter ending 2013-03-31 was $110.00K, a 19.71% decline year-over-year.
  • PROTHENA CORPORATION PUBLIC LIMITED COMPANY payments to acquire property, plant, and equipment for the quarter ending 2012-03-31 was $137.00K.
Period endPayments to Acquire Property, Plant, and Equipment 3 month
2013-03-31$110.00K
10-Q · filed 2013-05-15
2012-03-31$137.00K
10-Q · filed 2013-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10